Respiri to sell wheezo device and technology in the United States after securing FDA approval
Respiri’s initial target market in the US will be asthma suffers with an estimated 24.7 million adults and children living with the disease in the country.
FDA breathes life into Respiri’s US opportunities
Marjan Mikel, Respiri CEO, is looking to launch into the US market following the FDA’s approval to sell its flagship wheezo product, aiming to help kids getting whacked with asthma
Respiri (ASX:RSH) receives FDA tick for Wheezo
Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance for Wheezo.
Wheezo monitors wheezing to help manage and improve asthma. The technology can also share data with caregivers, physicians and other health care professionals.
Respiri (ASX:RSH) share price on watch following FDA approval
The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.
Respiri gets FDA approval for wheezo device
Medtech firm Respiri has secured a significant win before the US regulator, with the FDA approving its wheezo device and app for sale.
Respiri Health scores FDA tick after 21 years of toil
More than two decades after listing on the ASX, small cap medical device company Respiri Health has entered the commercialisation phase of its asthma monitoring technology business, achieving US Food and Drug Administration approval.
Respiri rolls out wheezo device distribution with Pharmacy 4 Less group
Special Report: Respiratory health company Respiri has entered into a sales and marketing partnership for its wheezo devices for asthma management with Pharmacy 4 Less.
Respiri teams up with Pharmacy 4 Less group for wheezo sales
Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for the sale of its asthma management device wheezo commencing early next year.
Respiri reasserts full-year revenue guidance after locking in key product order, shares climb
Special Report: Respiri’s deal with Cipla will allow it to boost distribution of its wheezo asthma management device via direct pharmacy sales.
Breathe Easy – Channel 7
Radio Interview – Michael Clarke hails new technology to help those suffering with asthma
Summer brings with it not only the threat of skin cancer, but dangers to those suffering from asthma.”
NEW TOOL FOR ASTHMA MANAGEMENT
Cricket great and pharmacy leader join to welcome the launch of a new pharmacy-based asthma management product
Her biggest cheerleader! Pip Edwards’ boyfriend Michael Clarke sports her brand P.E Nation head-to-toe as he helps to launch an asthma management device in Sydney
The cricketing legend, 39, stepped out to officially launch asthma management device ‘Wheezo’ in Sydney – and was dripping head-to-toe in his girlfriend Pip’s gym attire, P.E Nation, for the occasion.
EXCLUSIVE: Michael Clarke opens up about the joy of raising his “sporty princess” daughter, Kelsey Lee, as he champions a cause close to his heart
”It’s nice to see her growing up with that smile on her face.”
wheezo becomes Co-Major of the Game Changers
AFTER joining the Carlton family in August as an official AFLW partner, wheezo will now step up its support of the Club’s AFLW side.
A breath of fresh air for asthma sufferers
Asthma is one of the world’s most prevalent and debilitating chronic diseases with 339 million people affected by the condition. The University of Washington’s Institute for Health Metrics and Evaluation (IHME) estimates that 420,000 people died from asthma worldwide in 2016.
Respiri shaves costs as wheezo technology continues to be well-received
With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins.
Respiri details ‘exceptional’ cost savings to wheezo production
Special Report: Respiri Limited (ASX:RSH) expects its gross product margins for its wheezos to be 30 per cent higher than forecast, as the eHealth company has devised less-expensive ways to produce the asthma management device.
Respiri ‘pleased’ with wheezo feedback from initial sales and marketing
Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it has received from pharmacists and partner Cipla Australia.
Initial interest for Respiri’s asthma management wheezo device ‘exceeding expectations’
Multinational pharmaceutical company Cipla Australia says several key banner groups have come onboard to sell Respiri Limited’s (ASX:RSH) wheezo wheeze-detection device, which Cipla is supplying to select pharmacies to help asthma patients better manage their conditions.
Respiri files new patent application for wheezo asthma management device
Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algorithm for its wheezo asthma management device.
Respiri takes steps to secure intellectual property with another patent filing
Special Report: Melbourne-based asthma assessment company Respiri is taking steps to protect its commercial advantage before its Australian launch with another patent filing.
Investors line up to give Respiri cash as wheezo launches into Australian pharmacies
Respiri Limited has completed an oversubscribed $12.5 million to fund the launch of its wheezo asthma management device.
Respiri engages Chinese production to up asthma device manufacturing
Medtech company Respiri (ASX: RSH) has continued its long path towards commercialisation of its asthma diagnostics device ‘wheezo’, having entered into a global manufacturing agreement with Entech Electronics for 12,000 devices.
Respiri share price soars 7% on partnership agreement
The Respiri Limited (ASX: RSH) share price is up 6.82% to 23.5 cents in early afternoon trading. The surge in the Respiri share price comes following the company’s announcement this morning of a binding electronic manufacturing services (EMS) agreement with Entech Electronics for Respiri’s wheezo™ product.
Respiri unveils promising wheezo clinical study results
Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting the presence or absence of wheeze in patients with chronic respiratory ailments.
Respiri clinical trial shows ‘substantial agreement’ with doctor stethoscope test for asthma detection
Special Report: Respiri remains on track to commercialise its wheezo™ asthma detection device before the end of the year.
eHealth company Respiri (ASX:RSH) has continued its run of positive news flow, with the release of new clinical trial data this morning.
Respiri catches a screamer with Carlton AFLW deal
Ehealth business Respiri (ASX:RSH) has taken its biggest mark yet for 2021, signing on with the Carlton Football Club’s AFLW team for the upcoming season.
The partnership announcement will see Respiri’s wheezo device and software-as-a-service (SaaS) monitoring system supported by Carlton’s AFLW team to bring awareness of the importance of asthma management to the forefront of the community.
Respiri teams up with Carlton Football Club to promote wheezo device
A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, commencing from next season.
Respiri signs referral agreement with APA to proliferate wheezo in Australia
eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the Australian Patients Association (APA).
Respiri, APA partner to give 1.1m patients access to wheezo study
Special Report: Respiri (ASX:RSH) has won over the Australian Patients Association (APA) for its wheezo Experiential Program, a real-world asthma management study designed to support people living with the condition.
StockTalk: How are ASX medtechs responding to skyrocketing healthcare spending?
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses skyrocketing healthcare spending and its impact on the medtech sub-sector.
View Older Respiri News
Respiri partners with Australian Patients Association for wheezo study – August 12, 2020
Read article
Source: smallcaps.com.au
Respiri eyes maiden 2021 revenue of $6-8m – July 27, 2020
Read article
Source: stockhead.com.au
eHealth SaaS provider Respiri targets $6-8m revenue for 2021 – July 27, 2020
Read article
Source: smallcaps.com.au
Respiri’s biggest deal yet gives it access to the world – July 17, 2020
Read article
Source: stockhead.com.au
Respiri secures global sales and distribution agreement for wheezo asthma monitoring device – July 17, 2020
Read article
Source: smallcaps.com.au
Add these 3 ASX medical technology companies to your watch list – July 2, 2020
Read article
Source: fool.com.au
Respiri launches asthma education plan to support pharmacists – June 17, 2020
Read article
Source: stockhead.com.au
Respiri teams up with Pharmacy Guild to educate pharmacists on asthma management – June 16, 2020
Read article
Source: themarketherald.com.au
Respiri signs service agreement with the Pharmacy Guild of Australia for education of pharmacists – June 16, 2020
Read article
Source: newsnreleases.com.au
Respiri launches wheezo asthma monitoring app – June 15, 2020
Read article
Source: bioworld.com.au
Shareholders back Respiri’s new story with strong support for capital raise – May 6, 2020
Read article
Source: stockhead.com.au
Shareholders back Respiri in heavily oversubscribed share purchase plan – May 6, 2020
Read article
Source: smallcaps.com.au
Respiri pushes ahead with regional expansion after signing key distribution deal – April 30, 2020
Read article
Source: stockhead.com.au
Respiri to enter asthma telehealth, wheezo commercialisation looms – April 14, 2020
Read article
Source: thesentiment.com.au
Stock Talk: TeleHealth in a COVID-19 world and beyond – April 7, 2020
Read article
Source: stockhead.com.au
Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China – March 19, 2020
Read article
Source: smallcaps.com.au
Health-tech company Respiri finds demand amid the chaos; closes $2m share placement – March 26, 2020
Read article
Source: stockhead.com.au
Remote control: 5 medtechs set to benefit from the surge in demand for tele-health solutions – March 24, 2020
Read article
Source: stockhead.com.au
Remote control: 5 medtechs set to benefit from the surge in demand for tele-health solutions – March 24, 2020
Read article
Source: stockhead.com.au
JOIN OUR NEWSLETTER
Be the first to hear of Respiri’s latest news and subscribe to the bi-monthly newsletter here.